Solid Biosciences (SLDB) Accounts Payables (2017 - 2024)
Historic Accounts Payables for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $3.5 million.
- Solid Biosciences' Accounts Payables rose 8219.18% to $3.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.5 million, marking a year-over-year increase of 8219.18%. This contributed to the annual value of $2.0 million for FY2023, which is 3724.52% down from last year.
- Per Solid Biosciences' latest filing, its Accounts Payables stood at $3.5 million for Q3 2024, which was up 8219.18% from $2.5 million recorded in Q2 2024.
- Solid Biosciences' Accounts Payables' 5-year high stood at $5.6 million during Q1 2023, with a 5-year trough of $1.7 million in Q1 2024.
- For the 5-year period, Solid Biosciences' Accounts Payables averaged around $3.5 million, with its median value being $3.2 million (2022).
- Over the last 5 years, Solid Biosciences' Accounts Payables had its largest YoY gain of 8219.18% in 2024, and its largest YoY loss of 6907.95% in 2024.
- Quarter analysis of 5 years shows Solid Biosciences' Accounts Payables stood at $3.3 million in 2020, then surged by 36.32% to $4.5 million in 2021, then fell by 27.45% to $3.2 million in 2022, then plummeted by 37.25% to $2.0 million in 2023, then skyrocketed by 70.18% to $3.5 million in 2024.
- Its last three reported values are $3.5 million in Q3 2024, $2.5 million for Q2 2024, and $1.7 million during Q1 2024.